The abstract is read at the publisher; the summary is JClub's.
In youth with prediabetes and type 2 diabetes, β-cell function deteriorates faster than in adults, with reductions of 40% in prediabetes and >80% in recent-onset type 2 diabetes.
- Why it matters: The work addresses how β-cell failure drives worsening glycemia and why current glucose-lowering therapies cannot stop the decline over time.
- What they did: It evaluates β-cell responses to intravenous and oral glucose while accounting for prevailing insulin sensitivity, and tracks β-cell function longitudinally across age groups in clinical trials.
- The result: β-cell dysfunction progression over time is linked to deteriorating glycemia, and none of the currently available glucose-lowering agents halts this decline.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.